…
Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs for the treatment of various cancers. The company is involved in the research, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services. The company was founded in 1977 and is headquartered in Houston, Texas.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Burzynski Research (OTC Pink: BZYR) is a small, thinly reported public company tied to the Burzynski group's development of oncology therapies. Long-term growth may depend on positive clinical results, regulatory approvals, and successful commercialization, which could support upside if milestones are achieved despite limited disclosure.
Key investment risks are high clinical and regulatory execution risk, limited financial and reporting transparency, low OTC liquidity, and potential legal or reputational uncertainty.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-02-28 | 2024-02-29 | 2023-02-28 | 2022-02-28 | 2021-02-28 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-02-28 | 2024-02-29 | 2023-02-28 | 2022-02-28 | 2021-02-28 |
| Income before tax | -1.39M | -1.34M | -0.92M | -0.98M | -1.20M |
| Net income | -1.39M | -1.34M | -0.92M | -0.98M | -1.20M |
| Selling general administrative | 0.34M | 0.40M | 0.20M | 0.22M | 0.28M |
| Selling and marketing expenses | - | 0.07M | - | - | - |
| Ebit | - | -2.67M | - | -0.98M | -1.30M |
| Ebitda | -1.39M | -1.34M | -0.92M | -0.98M | -1.30M |
| Depreciation and amortization | - | 1.34M | - | - | - |
| Operating income | -1.39M | -1.34M | -0.92M | -0.98M | -1.30M |
| Other operating expenses | 1.39M | 1.34M | 0.92M | 0.98M | 1.30M |
| Interest expense | - | - | - | 0.00M | 0.00M |
| Tax provision | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Income tax expense | - | -1.34M | - | - | -0.10M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 1.39M | 1.34M | 0.92M | 0.98M | 1.30M |
| Total other income expense net | - | -0.00M | - | - | 0.10M |
| Net income from continuing ops | -1.39M | -1.34M | -0.92M | -0.98M | -1.20M |
| Net income applicable to common shares | - | - | - | -0.98M | -1.20M |
| Breakdown | 2025-02-28 | 2024-02-29 | 2023-02-28 | 2022-02-28 | 2021-02-28 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-02-28 | 2024-02-29 | 2023-02-28 | 2022-02-28 | 2021-02-28 |
| Total assets | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Other current assets | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Total liab | 0.04M | 0.03M | 0.02M | 0.00M | 0.05M |
| Total stockholder equity | -0.04M | -0.03M | -0.01M | 0.00M | -0.05M |
| Other current liab | 0.03M | 0.02M | 0.00M | 0.00M | 0.01M |
| Common stock | 0.13M | 0.13M | 0.13M | 0.13M | 0.13M |
| Capital stock | 0.13M | 0.13M | 0.13M | 0.13M | 0.13M |
| Retained earnings | -129.48M | -128.09M | -126.75M | -125.84M | -124.86M |
| Cash | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total current liabilities | 0.04M | 0.03M | 0.02M | 0.00M | 0.05M |
| Net debt | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M |
| Other stockholder equity | 129.30M | 127.93M | 126.61M | 125.71M | 124.68M |
| Total current assets | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Net tangible assets | - | - | - | 0.00M | -0.05M |
| Accounts payable | 0.02M | 0.01M | 0.01M | 0.00M | 0.03M |
| Non current assets total | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Breakdown | 2025-02-28 | 2024-02-29 | 2023-02-28 | 2022-02-28 | 2021-02-28 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-02-28 | 2024-02-29 | 2023-02-28 | 2022-02-28 | 2021-02-28 |
| Change to liabilities | - | - | - | -0.03M | -0.03M |
| Total cash from financing activities | 0.39M | 0.52M | 0.25M | 0.33M | 0.39M |
| Change to operating activities | - | - | - | -0.01M | 0.02M |
| Net income | -1.39M | -1.34M | -0.92M | -0.98M | -1.20M |
| Change in cash | -0.00M | 0.00M | -0.00M | 0.00M | -0.00M |
| Begin period cash flow | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| End period cash flow | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total cash from operating activities | -0.39M | -0.52M | -0.25M | -0.33M | -0.39M |
| Issuance of capital stock | 0.39M | 0.52M | - | - | - |
| Other cashflows from financing activities | 0.39M | 0.52M | 0.25M | 0.33M | 0.39M |
| Change to netincome | - | - | - | 0.70M | 0.82M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.01M | 0.01M | 0.01M | -0.04M | -0.01M |
| Stock based compensation | 0.98M | 0.80M | - | - | - |
| Other non cash items | 0.01M | 0.80M | 0.65M | 0.70M | 0.82M |
| Free cash flow | -0.39M | -0.52M | -0.25M | -0.33M | -0.39M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BZYR Burzynski Research |
- -% |
0.00 | - | - | 7455.69 | 2190.81 | 1749.70 | -5.28 |
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs for the treatment of various cancers. The company is involved in the research, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services. The company was founded in 1977 and is headquartered in Houston, Texas.
| Name | Title | Year Born |
|---|---|---|
| Dr. Stanislaw R. Burzynski | Chairman, CEO & Pres | 1943 |
| Mr. Patryk P. Goscianski | Treasurer & Sec. | 1978 |
| Dr. Stanislaw R. Burzynski M.D., Ph.D. | Chairman, CEO & President | 1943 |
| Mr. Patryk P. Goscianski M.B.A. | CFO, Treasurer & Secretary | 1978 |
| Dr. Tomasz Janicki M.D. | Vice President of Clinical Trials | 1966 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.